Blood
Articles in this Issue
Mortality in sickle cell disease: A report from the grndad registry
Abstract Sickle cell disease (SCD) is associated with a high level of morbidity and early loss of life. A widely cited analysis modeling lif...
Off-the-shelf CD117 CAR-iNKT cells as a safe and effective allogeneic immunotherapy targeting AML and its immunosuppressive microenvironment
Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with a five-year overall survival rate of approximately...
Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience
Abstract Background: Glofitamab, a bispecific CD20xCD3 T-cell engager, is FDA-approved for R/R DLBCL after ≥2 prior lines of therapies (LOT)...
Hemolysis impairs hepatic regeneration in sickle cell disease via altered kupffer cell dynamics and inflammation
Abstract Sickle Cell Disease (SCD) is characterized by the release of hemoglobin and heme into the circulation, saturation of related plasma...
Mortality trends in patients with mantle cell lymphoma with or without a COVID-19 diagnosis
Abstract Introduction: Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma (NHL) that accounts for 5‒7% of all lymphomas....
Clinical outcomes and barriers of autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma in a non-transplant center: Assessing the impact of transplant accessibility on racial minorities
Abstract Autologous Hematopoietic stem cell transplant (autoHSCT) has remained the cornerstone in the management of multiple myeloma (MM), w...
Prevalence and mortality of infections following CAR T-cell therapy in children, adolescents, and young adults: A systematic review and meta-analysis
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of children, adolescents, and young adu...
Guaranteed care, uncertain meals: When universal coverage fails to feed
Abstract Background: Food insecurity (FI), the lack of reliable access to safe and nutritious food, is a major challenge for individuals und...
Early and sustained palliative care intervention is not superior to on-demand palliative care referral for patients with high-risk leukemias or myelodysplastic syndrome
Abstract Background. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) are less likely to receive palliative care (PC) ser...
A first-in-primate In Vivo CRISPR/Cas9 screen in a rhesus macaque model identifies drivers of CAR-T expansion, tissue tropism and persistence
Abstract Background: Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized treatment for B-cell malignancies, yet >50%...
Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab
Abstract Background The historical outcomes for patients with relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia (B-cell AL...
Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study
Abstract Abstract Background: Current therapeutic strategies for Myelodysplastic/Myeloproliferative Neoplasms overlap syndromes (MDS/MPN) re...
Support isn't always supportive: Relational and cultural misalignment in black sickle cell disease adult caregiving norms
Abstract Background As advances in care extend life expectancy, many adults with sickle cell disease (SCD) require susta...
Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.
Abstract Background Adenovirus is a common lytic DNA virus. However, it causes severe disease in immunocompromised hosts. While Cidofovir is...
Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data
Abstract Introduction Venetoclax in combination with a hypomethylating agent has become a standard treatment for patient...
CHG combined with venetoclax and azacytidine as induction chemotherapy in acute myeloid leukemia
Abstract Background: The survival rate of patients diagnosed with acute myeloid leukemia (AML) has shown improvement in recent decades. Howe...
Retrieval-Augmented GPT-4 Improves NCCN-Concordant Lymphoma Treatment Recommendations
Abstract While the use of NCCN guidelines is essential in lymphoma care, adherence among oncologists remains highly variable. Real-world con...
Shifting symptom profiles and accelerated diagnosis in AL amyloidosis: Findings from ARC community surveys 2022–2024
Abstract Introduction: Light chain amyloidosis (AL) is a progressive, multisystemic disease caused by the buildup of misfolded immunoglobuli...
Spatial transcriptomic dissection of the myeloproliferative neoplasm niche uncovers mutant clone interactions and microenvironmental rewiring
Abstract The development of myeloid neoplasms involves complex cell-cell communication and functional changes within the bone marrow niche....
Real-world outcomes of direct oral anticoagulants versus warfarin in patients with single-positive antiphospholipid antibody syndrome: A trinetx cohort analysis
Abstract Background The use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS) remains a topic of discussion. Current...
Expert consensus on the clinical management of congenital thrombotic thrombocytopenic purpura in Asia-Pacific: A modified Delphi panel
Abstract Background Congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome or hereditary TTP (hTTP),...
Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.
Abstract Introduction: Response assessment after induction is a key milestone in the treatment and care of acute myeloid...
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Abstract Introduction: Patients (pts) with R/R DLBCL ineligible for chimeric antigen receptor T cell (CAR T) therapy or autologous stem cell...
NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1/STAT3/SPP1 axis.
Abstract Introduction: Macrophages (MΦs) are key components of the multiple myeloma (MM) tumor microenvironment (TME) and contribute to drug...
Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration
Abstract Extramedullary infiltration (EMI) is a major cause of treatment failure and relapse in acute myeloid leukemia (AML), particularly i...